long-acting release drug products for opioid use disorder, chronic pain, and major depressive disorder. Taiwan. 2016. Stemchymal® allogeneic stem cells products. USA. 2018. Immunotherapies for cancer with myeloid checkpoint inhibitors. Taiwan.

With an industry-leading international team, we play a pivotal leading role in Taiwan's venture capital and private equity market. Our Leadership Team. ... Chair of Regional Healthcare Practice at CDIB Capital Group: James Ho: Supervise asset management and investment management related to Healthcare sector:

CDIB Capital Healthcare Ventures II led the series B funding round for Acepodia and helped the company successfully raise US$47 million in a very short period of time. Professional Capital Market Experience. Even during phases of market volatility, our vast resources and experience in the capital market get our partners results. ...

Ms. Hsu has 25 years of experience in venture capital, and has participated in the establishment of CDIB Capital Healthcare Ventures and CDIB Capital Healthcare Ventures II since 2012. Career Highlights. Auditor. KPMG. Investment Manager. Central Investment Holding. Senior Vice President.

Venture and Growth Capital. Overview. Strategies . Overview. ... Healthcare Strategies . We focus on high-potential startups in biotech and pharmaceuticals, med-tech, and digital health care industries, along with broader biomedical and healthcare service sectors. ... primarily in North America and Asia Pacific. We also invest across the ...

Leadership in Venture Capital, Private Equity Investment & Asset Management. China Development Industrial Bank was officially renamed CDIB Capital Group with this underlying business transformation in March 2017. This evolution is underpinned by the goal of becoming the leading private equity and venture capital fund manager in the Asia-Pacific ...

Fax +852 2231 8601. Address Suites 701-703, ICBC Tower, 3 Garden Road, Central, Hong Kong. CDIB Private Equity (China) Registered in Shanghai, CDIB Private Equity (China) Corporation was established in 2012 as a wholly-owned subsidiary of CDIB capital Group that raises and manages renminbi-denominated private equity funds in Mainland China.

CDF reports April after-tax profit of NT$2.42 billion. After-tax profit for the first four months reached NT$10.63 billion, and EPS was NT$0.64. China Development Financial Holding Corporation (hereinafter referred to as "CDF") reported today its profit for the month of April.

Biomedicine is one of our key investment areas. We have successfully led Acepodia’s B round of funding and helped them develop an innovative cancer treatment. We offer full support, from corporate governance to capital market, to help WellJoint (Shanghai) Technology make a stand in the industry, become a listed company, and achieve milestones ...

XREX is a blockchain-enabled financial institution working with banks, regulators, and users to redefine banking together. XREX provides enterprise-grade banking services to small to medium-sized businesses (SMBs) in or dealing with emerging markets, and novice-friendly financial services to individuals worldwide.